COMP <GO>
MANE vs LGND // EV/EBITDA & P/E VALUATION
Veradermics Incorporated (NYSE) VS. Ligand Pharmaceuticals Incorporated (NASDAQ) • 15-METRIC TALLY: MANE 2
— LGND 8
■ METRIC PARITY
LAST: $129.53 (-7.27%) • MKT CAP: $5.84B
valuation
—
LAST: $307.02 (-4.87%) • MKT CAP: $6.43B
valuation
95.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MANE VS. LGND)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MANE | LGND | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.90% | 3.00% | -14.90 | LGND | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 95.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.19% | 0.77% | -1.96 | LGND | /fcf-yield <GO> |
| Operating Margin | -4.30% | 15.30% | -19.60 | LGND | /operating-margins <GO> |
| Net Profit Margin | -4.20% | 46.40% | -50.60 | LGND | /net-margins <GO> |
| Revenue Growth (YoY) | 4.40% | 60.40% | -56.00 | LGND | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 8.40 | +17.60 | MANE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | LGND | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.4 | 61.9 | -1.50 | LGND | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.07 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 42.7x | -18.70 | MANE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.84B | $6.43B | -$598.0M | LGND | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MANE REV | LGND REV | MANE GROSS % | LGND GROSS % | MANE FCF | LGND FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $202.6M | $268.1M | — | — | -$71.6M | $48.9M |
| FY 2024 | $75.0M | $167.1M | — | — | -$23.7M | $95.2M |
| FY 2023 | — | $131.3M | — | — | — | $43.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MANE // BETA 1.07
LGND // BETA 1.07